Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Retired Vice Minister Happy to See Stage Set for Timely Price Revisions
July 12, 2017
- MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
- Further Transformation beyond Pricing Overhaul Inevitable: Outgoing MHLW Economic Affairs Chief
July 10, 2017
- Applications for Partial Modification to Suffice to Change Manufacturing Processes for Biopharmaceuticals: MHLW Notification
July 7, 2017
- MHLW to Enhance Awareness about Tougher Controls on Private Importing of Drugs by Doctors
July 7, 2017
- MHLW Floats Standard Processing Time for Cost-Effective Assessments: Chuikyo
July 6, 2017
- Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
- Drugs Containing Codeine to Be Contraindicated in Children Younger than 12: MHLW Notifications
July 6, 2017
- Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017
- Add Sclerosing Cholangitis to ADR List in Opdivo Label: MHLW
July 5, 2017
- MHLW OKs Spinraza, Tenelia-Canaglu Combo, and More
July 4, 2017
- MHLW Calls for Surprise Inspection for API Makers
July 3, 2017
- Revised GPSP Ministerial Ordinance Will Establish“Post-Marketing Database Surveys”: MHLW
July 3, 2017
- MHLW to Provide Administrative Guidance in 23 Cases of Ethical Drug Advertising Activities
July 3, 2017
- MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
- MHLW Issues Notification to Redefine “Three Officer System” at Drug Makers
June 29, 2017
- Yamamoto Chemical Slapped with 22-Day Biz Suspension
June 29, 2017
- JMA’s Nakagawa Wants Clear Definitions for Original Drug, LLP, AG, Gx: Chuikyo
June 29, 2017
- “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo
June 29, 2017
- Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method
June 29, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…